Compare Abbott Laboratories (ABT) vs Deutsche Bank AG (DB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Deutsche Bank AG — how do they compare? Abbott Laboratories trades at $95.65 (market cap $166.94B), while Deutsche Bank AG trades at $35.11 (market cap $70.38B). The key difference: Abbott Laboratories is far larger — about 2.4× Deutsche Bank AG's market cap, and Deutsche Bank AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| ABT | DB | |
|---|---|---|
Market Cap | $166.94B | $70.38B |
Sector | Health | Financials |
52-Week High | $136.62 | $40.33 |
52-Week Low | $82.57 | $28.37 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Deutsche Bank (DB) trades at $36.64, up 2.18% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamental momentum with three consecutive quarterly EPS beats and a net income margin of 21.98% for 2025. Recent strategic moves include selling its India retail unit to Kotak to sharpen focus on higher-growth businesses, while maintaining a dividend payout of $1.00 for H1-26.
The outlook remains positive with revenue growth to $32.2B projected for 2026 and a profit margin of 21.97%. Investment opportunities include attractive valuation with P/E of 10.29 and P/B of 0.8, but risks involve negative operating cash flow of -$28.58B in 2024 and competitive pressures from JPMorgan's expansion in Germany.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
